Applied Genetic Technologies CORP: insider trades · United States · SEC (Form 4)

About Applied Genetic Technologies CORP

Applied Genetic Technologies Corp. (AGTC) is a United States biotech company historically listed on the NASDAQ, positioned in the healthcare and gene-therapy segment. Founded in 1999, the company emerged from academic and translational research in genetic medicine and built its strategy around a proprietary adeno-associated virus (AAV) gene-therapy platform aimed at rare inherited diseases. Its operational headquarters have been in Alachua, Florida, reflecting its roots in the Gainesville-area biotechnology cluster. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai)) AGTC’s core business has centered on clinical and preclinical gene-therapy development, with an initial emphasis on ophthalmology. Public filings describe programs directed at serious rare eye diseases, including X-linked retinitis pigmentosa, achromatopsia, and X-linked retinoschisis, and also show the company expanding its research footprint into other rare-disease areas over time. The strategic logic is straightforward: target monogenic conditions with clear biology, high unmet medical need, and the potential for durable benefit if a gene therapy can successfully deliver functional genetic material to the relevant tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai)) From a competitive standpoint, AGTC operated in a highly specialized, capital-intensive part of biotech. In gene therapy, competition comes from other platform developers and clinical-stage companies rather than from traditional pharma alone. Differentiation depends on vector design, transgene expression, tissue targeting, manufacturing know-how, and clinical execution. AGTC’s positioning was built on its AAV expertise, intellectual property, and collaborations with external scientific partners, all of which were meant to support development in niche ophthalmic and other orphan indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai)) The company should be viewed more as a development-stage asset than a commercial product business. Its value proposition historically came from the pipeline, research capabilities, licensing activity, and collaboration agreements rather than from large-scale product sales. SEC disclosures note that AGTC had not generated product revenue and depended on external financing and continued R&D progress to advance its candidates. For investors, that means the equity story is driven by clinical milestones, regulatory progress, partnership potential, and cash runway rather than stable operating earnings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai)) Recent market context also matters. The company has been followed for SEC reporting activity, including Form 4 insider transactions, which can be relevant for small-cap biotech investors assessing insider sentiment and governance transparency. In practical terms, AGTC fits the profile of a U.S.-listed NASDAQ biotech: scientifically focused, milestone-driven, and highly sensitive to clinical data, financing conditions, and regulatory developments. For French-speaking investors in France, Belgium, or Switzerland, the key takeaway is that AGTC is a speculative gene-therapy name with a rare-disease focus, a Florida base, and a long-duration risk/reward profile typical of early-stage biotechnology. ([secform4.com](https://www.secform4.com/insider-holders/1273636.html?utm_source=openai))